| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -11,374,219 | -7,291,046 |
| Net proceeds from sales of common stock | 8,854,797 | 8,854,797 |
| Payments of deferred offering costs | 455,726 | - |
| Net cash provided by financing activities | 8,399,071 | 8,854,797 |
| Net change in cash | -2,975,148 | 1,563,751 |
| Cash and cash equivalents at beginning of period | 5,811,064 | - |
| Cash and cash equivalents at end of period | 2,835,916 | - |
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)